Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States

被引：0
|
作者：
Cheryl Neslusan
Anna Teschemaker
Michael Willis
Pierre Johansen
Lien Vo
机构：
[1] Janssen Global Services,
[2] LLC,undefined
[3] The Swedish Institute for Health Economics,undefined
[4] Janssen Scientific Affairs,undefined
[5] LLC,undefined
来源：
Diabetes Therapy | 2018年 / 9卷
关键词：
Canagliflozin; Cost-effectiveness; Dapagliflozin; Health economics; Modeling; QALY; Sodium glucose co-transporter 2 inhibitor; Type 2 diabetes mellitus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：565 / 581
页数：16
相关论文
共 50 条
  • [1] Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States
    Neslusan, Cheryl
    Teschemaker, Anna
    Willis, Michael
    Johansen, Pierre
    Vo, Lien
    [J]. DIABETES THERAPY, 2018, 9 (02) : 565 - 581
  • [2] COST-EFFECTIVENESS OF CANAGLIFLOZIN VERSUS DAPAGLIFLOZIN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES IN CHINA
    Hou, X.
    Wan, X.
    Li, Y.
    Ding, Y.
    Wu, B.
    [J]. VALUE IN HEALTH, 2019, 22 : S144 - S144
  • [3] Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China
    Hou, Xingyun
    Wan, Xu
    Wu, Bin
    [J]. FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [4] Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting
    Stafford, Sara
    Bech, Peter G.
    Fridhammar, Adam
    Miresashvili, Nino
    Nilsson, Andreas
    Willis, Michael
    Liu, Aiden
    [J]. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2022, 20 (04) : 543 - 555
  • [5] Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting
    Sara Stafford
    Peter G. Bech
    Adam Fridhammar
    Nino Miresashvili
    Andreas Nilsson
    Michael Willis
    Aiden Liu
    [J]. Applied Health Economics and Health Policy, 2022, 20 : 543 - 555
  • [6] COST-EFFECTIVENESS ANALYSIS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) AS AN ADD-ON TO METFORMIN (MET) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN THE UNITED STATES
    Neslusan, C.
    Teschemaker, A.
    Martin, S.
    Willis, M.
    Johansen, P.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A248 - A248
  • [7] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) 10MG AND EMPAGLIFLOZIN (EMPA) 25MG IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) AS MONOTHERAPY IN THE UNITED KINGDOM
    Schroeder, M.
    Johansen, P.
    Willis, M.
    Neslusan, C.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A607 - A607
  • [8] COST-EFFECTIVENESS OF CANAGLIFLOZIN VERSUS SITAGLIPTIN WHEN ADDED TO METFORMIN AND SULFONYLUREA IN TYPE 2 DIABETES IN CANADA
    Sabapathy, Suthakar
    Neslusan, Cheryl
    Yoong, Kim
    Teschemaker, Anna
    Johansen, Pierre
    Willis, Michael
    [J]. JOURNAL OF POPULATION THERAPEUTICS AND CLINICAL PHARMACOLOGY, 2016, 23 (02): : E151 - E168
  • [9] THE COST-EFFECTIVENESS EVALUATION OF CANAGLIFLOZIN VERSUS DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN MONOTHERAPY IN SPAIN
    Nielsen, A. T.
    Pitcher, A.
    Lovato, E.
    Schubert, A.
    Hemels, M.
    Neslusan, C.
    Gonzalez, B.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A61 - A61
  • [10] Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries
    Sabale, Ugne
    Ekman, Mattias
    Granstrom, Ola
    Bergenheim, Klas
    McEwan, Phil
    [J]. PRIMARY CARE DIABETES, 2015, 9 (01) : 39 - 47
12345